Get to know our clinical trials
Clinical trial of REGN4018 administered in patients with recurrent ovarian cancer
THE MAIN OBJECTIVE OF THIS STUDY IS TO: 1) EXPLORE THE SAFETY OF REGN4018 AND DETERMINE THE BEST DOSE OF REGN4018 THAT CAN BE GIVEN ALONE OR WITH CEMIPLIMAB TO PATIENTS WITH OVARIAN CANCER; 2) MEASURE THE LEVELS OF REGN4018 AND/OR CEMIPLIMAB IN YOUR BODY. THIS IS CALLED PHARMACOKINETICS; AND 3) EXAMINE FOR SIGNS THAT REGN4018 ALONE OR WITH CEMIPLIMAB CAN TREAT YOUR CANCER.
Technical Summary
- PHASE I/II STUDY OF REGN4018 (A BISPECIFIC MUC16XCD3 ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER
- Code EudraCT: 2019-003298-24
- Protocol number: R4018-ONC-1721
- Promoter: Regeneron Pharmaceuticals, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.